» Articles » PMID: 16186811

Engineering the Fc Region of Immunoglobulin G to Modulate in Vivo Antibody Levels

Overview
Journal Nat Biotechnol
Specialty Biotechnology
Date 2005 Sep 28
PMID 16186811
Citations 184
Authors
Affiliations
Soon will be listed here.
Abstract

We have engineered the Fc region of a human immunoglobulin G (IgG) to generate a mutated antibody that modulates the concentrations of endogenous IgGs in vivo. This has been achieved by targeting the activity of the Fc receptor, FcRn, which serves through its IgG salvage function to maintain and regulate IgG concentrations in the body. We show that an IgG whose Fc region was engineered to bind with higher affinity and reduced pH dependence to FcRn potently inhibits FcRn-IgG interactions and induces a rapid decrease of IgG levels in mice. Such FcRn blockers (or 'Abdegs,' for antibodies that enhance IgG degradation) may have uses in reducing IgG levels in antibody-mediated diseases and in inducing the rapid clearance of IgG-toxin or IgG-drug complexes.

Citing Articles

Anti-myeloperoxidase IgM B cells in anti-neutrophil cytoplasmic antibody-associated vasculitis.

Wortel C, van de Wetering R, Stork E, Kissel T, Reijm S, van der Woude D Nat Commun. 2025; 16(1):1582.

PMID: 39939347 PMC: 11822119. DOI: 10.1038/s41467-025-56786-x.


Reducing IgG accumulation via neonatal Fc receptor (FcRn) blockade relieves neuropathic pain.

Fiore N, Willcox K, Dayani D, Zuberi Y, Heijnen C, Grace P Brain Behav Immun. 2025; 125:371-387.

PMID: 39870199 PMC: 11903150. DOI: 10.1016/j.bbi.2025.01.015.


Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics.

Ou L, Setegne M, Elliot J, Shen F, Dassama L Chem Rev. 2025; 125(4):2120-2183.

PMID: 39818743 PMC: 11870016. DOI: 10.1021/acs.chemrev.4c00595.


Individualized Dosing of Efgartigimod in Patients With Generalized Myasthenia Gravis: Clinical Experience at a Single Center.

Silvestri N Muscle Nerve. 2025; 71(3):422-428.

PMID: 39744896 PMC: 11799394. DOI: 10.1002/mus.28334.


Binding to the neonatal Fc receptor enhances the pathogenicity of anti-desmoglein-3 antibodies in keratinocytes.

Zakrzewicz A, Vanderheyden K, Galaly Y, Feldhoff S, Sips M, Brinkhaus M Front Immunol. 2024; 15:1473637.

PMID: 39450168 PMC: 11499148. DOI: 10.3389/fimmu.2024.1473637.